Collegium Pharmaceutical (COLL)
Collegium Pharmaceutical on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
5.4M
Short interest
settlement 2026-10-15
7.2
Days to cover
+1.1 days vs prior
62.1%
Short share of volume
2026-11-02
18
Fails to deliver
settlement 2026-10-09
Thu 5 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in COLL is 5,375,283 shares, down 299,832 shares over the last month. Over the last 48 readings it ranged from 4,208,811 shares (15 July 2025) to 6,523,302 shares (14 August 2026). At the reported average volume of 750K shares a day that is 7.2 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/coll" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 5,375,283 | -2.6% | 749,870 | 7.17 |
| 2026-09-30 | 5,516,880 | -2.8% | 910,922 | 6.06 |
| 2026-09-15 | 5,675,115 | -6.4% | 941,430 | 6.03 |
| 2026-08-31 | 6,063,781 | -7.0% | 750,635 | 8.08 |
| 2026-08-14 | 6,523,302 | +28.4% | 979,471 | 6.66 |
| 2026-07-31 | 5,080,634 | -2.9% | 292,836 | 17.35 |
| 2026-07-15 | 5,233,514 | -4.3% | 467,575 | 11.19 |
| 2026-06-30 | 5,466,533 | +2.6% | 504,462 | 10.84 |
| 2026-06-15 | 5,328,343 | -5.9% | 407,626 | 13.07 |
| 2026-05-29 | 5,664,249 | -5.0% | 318,273 | 17.80 |
| 2026-05-15 | 5,965,080 | +0.5% | 533,619 | 11.18 |
| 2026-04-30 | 5,936,417 | -1.6% | 411,182 | 14.44 |
| 2026-04-15 | 6,034,635 | +9.1% | 561,823 | 10.74 |
| 2026-03-31 | 5,530,407 | +29.3% | 704,883 | 7.85 |
| 2026-03-13 | 4,277,886 | -7.0% | 578,654 | 7.39 |
| 2026-02-27 | 4,599,035 | -3.6% | 354,037 | 12.99 |
| 2026-02-13 | 4,773,126 | -0.4% | 303,058 | 15.75 |
| 2026-01-30 | 4,793,817 | -14.2% | 508,394 | 9.43 |
| 2026-01-15 | 5,587,144 | +3.2% | 516,783 | 10.81 |
| 2025-12-31 | 5,415,274 | +1.1% | 463,297 | 11.69 |
| 2025-12-15 | 5,353,853 | -8.9% | 525,982 | 10.18 |
| 2025-11-28 | 5,878,047 | +3.5% | 515,555 | 11.40 |
| 2025-11-14 | 5,679,812 | +5.6% | 746,660 | 7.61 |
| 2025-10-31 | 5,376,415 | +2.8% | 305,892 | 17.58 |
| 2025-10-15 | 5,230,993 | +0.8% | 320,223 | 16.34 |
| 2025-09-30 | 5,189,204 | +16.5% | 381,847 | 13.59 |
| 2025-09-15 | 4,454,362 | +3.0% | 507,479 | 8.78 |
| 2025-08-29 | 4,324,706 | -2.2% | 381,918 | 11.32 |
| 2025-08-15 | 4,420,810 | +4.9% | 494,737 | 8.94 |
| 2025-07-31 | 4,215,754 | +0.2% | 255,514 | 16.50 |
| 2025-07-15 | 4,208,811 | -3.3% | 295,996 | 14.22 |
| 2025-06-30 | 4,354,200 | -9.6% | 319,620 | 13.62 |
| 2025-06-13 | 4,816,415 | -1.8% | 268,439 | 17.94 |
| 2025-05-30 | 4,904,665 | -3.4% | 249,274 | 19.68 |
| 2025-05-15 | 5,076,419 | +11.3% | 350,827 | 14.47 |
| 2025-04-30 | 4,559,209 | +1.9% | 280,018 | 16.28 |
| 2025-04-15 | 4,473,183 | -1.3% | 465,586 | 9.61 |
| 2025-03-31 | 4,529,665 | -14.0% | 503,056 | 9.00 |
| 2025-03-14 | 5,267,787 | -2.7% | 406,746 | 12.95 |
| 2025-02-28 | 5,412,981 | +4.0% | 377,037 | 14.36 |
| 2025-02-14 | 5,206,789 | -8.3% | 299,103 | 17.41 |
| 2025-01-31 | 5,681,414 | +1.2% | 363,392 | 15.63 |
| 2025-01-15 | 5,615,727 | -6.1% | 526,918 | 10.66 |
| 2024-12-31 | 5,983,188 | -0.1% | 468,902 | 12.76 |
| 2024-12-13 | 5,989,136 | -1.9% | 450,539 | 13.29 |
| 2024-11-29 | 6,108,028 | -2.8% | 459,953 | 13.28 |
| 2024-11-15 | 6,285,123 | +1.3% | 557,078 | 11.28 |
| 2024-10-31 | 6,207,632 | +1.0% | 262,959 | 23.61 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of COLL volume is 62.1%, up 5.0 points over the last five sessions. Over the last 30 readings it ranged from 41.9% (29 October 2026) to 74.6% (1 October 2026). The latest reading is 5.4 points above the 30-session average of 56.7%, on 185K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 115K | 185K | 62.1% | 0 |
| 2026-10-30 | 85K | 146K | 58.0% | 0 |
| 2026-10-29 | 102K | 243K | 41.9% | 0 |
| 2026-10-28 | 86K | 150K | 57.1% | 0 |
| 2026-10-27 | 86K | 155K | 55.5% | 0 |
| 2026-10-26 | 124K | 218K | 57.1% | 0 |
| 2026-10-23 | 140K | 263K | 53.1% | 0 |
| 2026-10-22 | 105K | 230K | 45.7% | 0 |
| 2026-10-21 | 78K | 135K | 57.8% | 0 |
| 2026-10-20 | 132K | 241K | 54.7% | 0 |
| 2026-10-19 | 121K | 277K | 43.6% | 0 |
| 2026-10-16 | 114K | 208K | 55.0% | 0 |
| 2026-10-15 | 211K | 384K | 54.8% | 0 |
| 2026-10-14 | 168K | 261K | 64.4% | 0 |
| 2026-10-13 | 170K | 323K | 52.6% | 200 |
| 2026-10-12 | 113K | 181K | 62.5% | 0 |
| 2026-10-09 | 96K | 169K | 56.6% | 0 |
| 2026-10-08 | 104K | 161K | 64.8% | 0 |
| 2026-10-07 | 115K | 172K | 67.0% | 0 |
| 2026-10-06 | 121K | 196K | 61.5% | 0 |
| 2026-10-05 | 185K | 329K | 56.1% | 2,715 |
| 2026-10-02 | 153K | 272K | 56.4% | 100 |
| 2026-10-01 | 251K | 337K | 74.6% | 0 |
| 2026-09-30 | 163K | 251K | 64.7% | 0 |
| 2026-09-29 | 205K | 381K | 53.8% | 0 |
| 2026-09-28 | 112K | 246K | 45.7% | 0 |
| 2026-09-25 | 107K | 199K | 53.6% | 0 |
| 2026-09-24 | 145K | 269K | 53.8% | 0 |
| 2026-09-23 | 194K | 326K | 59.3% | 0 |
| 2026-09-22 | 96K | 168K | 56.8% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 9 October 2026, the fails-to-deliver balance in COLL is 18 shares, down 9,307 shares over the last settlement date. Over the last 30 readings it ranged from 6 shares (2 July 2026) to 20,204 shares (29 May 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-09 | 18 | $22.11 | $398 |
| 2026-10-05 | 9,325 | $22.02 | $205K |
| 2026-09-08 | 370 | $23.53 | $9K |
| 2026-09-02 | 28 | $24.00 | $672 |
| 2026-09-01 | 5,888 | $24.61 | $145K |
| 2026-08-28 | 13 | $26.44 | $344 |
| 2026-08-20 | 2,306 | $28.74 | $66K |
| 2026-08-06 | 25 | $35.74 | $894 |
| 2026-08-04 | 2,064 | $35.58 | $73K |
| 2026-07-24 | 160 | $35.59 | $6K |
| 2026-07-23 | 100 | $34.72 | $3K |
| 2026-07-22 | 100 | $35.85 | $4K |
| 2026-07-16 | 363 | $36.72 | $13K |
| 2026-07-09 | 54 | $35.83 | $2K |
| 2026-07-02 | 6 | $35.87 | $215 |
| 2026-06-30 | 10,889 | $35.98 | $392K |
| 2026-06-29 | 5,142 | $36.59 | $188K |
| 2026-06-18 | 12 | $33.68 | $404 |
| 2026-06-15 | 600 | $34.64 | $21K |
| 2026-06-09 | 187 | $33.27 | $6K |
| 2026-06-08 | 1,697 | $33.38 | $57K |
| 2026-06-05 | 100 | $32.69 | $3K |
| 2026-06-04 | 100 | $31.06 | $3K |
| 2026-06-03 | 9 | $30.48 | $274 |
| 2026-06-01 | 20,196 | $33.61 | $679K |
| 2026-05-29 | 20,204 | $33.37 | $674K |
| 2026-05-26 | 76 | $34.07 | $3K |
| 2026-05-08 | 4,902 | $39.33 | $193K |
| 2026-05-07 | 699 | $36.51 | $26K |
| 2026-05-05 | 500 | $34.58 | $17K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for COLL in the last 90 days. The most recent filings are listed below. Latest filing: SANTINI GINO (Director) on 2026-06-08.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-06-08 | SANTINI GINO | Director | Exercise or conversion | 9K | $16.49 | $143K | 112K |
| 2026-05-18 | Freund John Gordon | Director | Sell | 20 | $34.05 | $681 | 84K |
| 2026-05-15 | Freund John Gordon | Director | Sell | 4K | $34.54 | $143K | 84K |
| 2026-05-15 | Freund John Gordon | Director | Exercise or conversion | 9K | $16.49 | $143K | 88K |
| 2026-05-14 | Glancy Donovan Michael | Director | Grant | 17K | $0.00 | $0 | 17K |
| 2026-05-14 | Paya Carlos V | Director | Grant | 9K | $0.00 | $0 | 28K |
| 2026-05-14 | Lurker Nancy | Director | Grant | 9K | $0.00 | $0 | 27K |
| 2026-05-14 | Freund John Gordon | Director | Grant | 9K | $0.00 | $0 | 79K |
| 2026-05-14 | SANTINI GINO | Director | Grant | 9K | $0.00 | $0 | 104K |
| 2026-05-14 | Balice-Gordon Rita J. | Director | Grant | 9K | $0.00 | $0 | 61K |
| 2026-05-14 | BOHLIN GAREN G | Director | Grant | 9K | $0.00 | $0 | 71K |
| 2026-05-13 | Lurker Nancy | Director | Sell | 5K | $35.97 | $162K | 18K |
| 2026-05-11 | BOHLIN GAREN G | Director | Sell | 9K | $37.18 | $323K | 62K |
| 2026-05-11 | BOHLIN GAREN G | Director | Exercise or conversion | 9K | $16.49 | $143K | 71K |
| 2026-03-18 | Dieter David | EVP & General Counsel | Sell | 14K | $34.92 | $488K | 77K |
| 2026-03-17 | Dieter David | EVP & General Counsel | Tax withholding | 9K | $35.72 | $316K | 68K |
| 2026-03-09 | Dieter David | EVP & General Counsel | Sell | 6K | $36.65 | $228K | 91K |
| 2026-03-03 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 4K | $40.99 | $146K | 72K |
| 2026-03-03 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 46K | $40.36 | $1.9M | 75K |
| 2026-02-10 | Dieter David | EVP & General Counsel | Tax withholding | 3K | $46.75 | $130K | 97K |
| 2026-02-10 | Dieter David | EVP & General Counsel | Grant | 9K | $0.00 | $0 | 100K |
| 2026-02-10 | Dieter David | EVP & General Counsel | Grant | 22K | $0.00 | $0 | 91K |
| 2026-02-10 | Tupper Colleen | EVP & Chief Financial Officer | Tax withholding | 27K | $46.75 | $1.2M | 147K |
| 2026-02-10 | Tupper Colleen | EVP & Chief Financial Officer | Tax withholding | 12K | $46.75 | $555K | 174K |
| 2026-02-10 | Tupper Colleen | EVP & Chief Financial Officer | Grant | 33K | $0.00 | $0 | 186K |
| 2026-02-10 | Tupper Colleen | EVP & Chief Financial Officer | Grant | 26K | $0.00 | $0 | 153K |
| 2026-02-10 | Smith Thomas B | EVP and Chief Medical Officer | Tax withholding | 12K | $46.75 | $539K | 91K |
| 2026-02-10 | Smith Thomas B | EVP and Chief Medical Officer | Tax withholding | 6K | $46.75 | $276K | 102K |
| 2026-02-10 | Smith Thomas B | EVP and Chief Medical Officer | Grant | 23K | $0.00 | $0 | 108K |
| 2026-02-10 | Smith Thomas B | EVP and Chief Medical Officer | Grant | 14K | $0.00 | $0 | 85K |
| 2026-02-10 | Dreyer Scott | EVP & Chief Commercial Officer | Tax withholding | 22K | $46.75 | $1.0M | 122K |
| 2026-02-10 | Dreyer Scott | EVP & Chief Commercial Officer | Tax withholding | 10K | $46.75 | $466K | 143K |
| 2026-02-10 | Dreyer Scott | EVP & Chief Commercial Officer | Grant | 31K | $0.00 | $0 | 153K |
| 2026-02-10 | Dreyer Scott | EVP & Chief Commercial Officer | Grant | 19K | $0.00 | $0 | 123K |
| 2026-02-10 | Karnani Vikram | President and CEO | Tax withholding | 11K | $46.75 | $528K | 198K |
| 2026-02-10 | Karnani Vikram | President and CEO | Grant | 33K | $0.00 | $0 | 209K |
| 2026-02-10 | Karnani Vikram | President and CEO | Grant | 79K | $0.00 | $0 | 177K |
| 2025-12-08 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 6K | $48.66 | $315K | 104K |
| 2025-12-08 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 11K | $47.89 | $533K | 110K |
| 2025-12-08 | Dreyer Scott | EVP & Chief Commercial Officer | Exercise or conversion | 18K | $15.90 | $280K | 121K |
| 2025-12-05 | Balice-Gordon Rita J. | Director | Sell | 4K | $47.03 | $172K | 53K |
| 2025-11-12 | Karnani Vikram | President and CEO | Tax withholding | 9K | $47.35 | $425K | 97K |
| 2025-11-12 | Fallon John A. | Director | Sell | 35K | $47.21 | $1.6M | 65K |
| 2025-11-12 | Fallon John A. | Director | Exercise or conversion | 20K | $9.33 | $185K | 99K |
| 2025-11-12 | Fallon John A. | Director | Exercise or conversion | 15K | $16.49 | $247K | 80K |
| 2025-11-06 | Tupper Colleen | EVP & Chief Financial Officer | Sell | 5K | $41.28 | $201K | 127K |
| 2025-11-06 | Tupper Colleen | EVP & Chief Financial Officer | Sell | 25K | $40.38 | $1.0M | 132K |
| 2025-08-29 | Smith Thomas B | EVP and Chief Medical Officer | Sell | 17K | $38.42 | $672K | 70K |
| 2025-08-18 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 16K | $38.21 | $626K | 104K |
| 2025-08-18 | Dreyer Scott | EVP & Chief Commercial Officer | Exercise or conversion | 16K | $21.34 | $350K | 120K |
| 2025-08-15 | SANTINI GINO | Director | Sell | 5K | $37.19 | $201K | 95K |
| 2025-08-15 | SANTINI GINO | Director | Exercise or conversion | 15K | $13.45 | $202K | 100K |
| 2025-08-13 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 5K | $38.03 | $185K | 104K |
| 2025-08-13 | Dreyer Scott | EVP & Chief Commercial Officer | Exercise or conversion | 5K | $21.34 | $104K | 108K |
| 2025-08-13 | Rubric Capital Management LP | 10% owner | Sell | 25K | $37.85 | $946K | 3.1M |
| 2025-08-08 | Freund John Gordon | Director | Sell | 12K | $34.36 | $401K | 23K |
| 2025-06-09 | Freund John Gordon | Director | Sell | 7K | $30.62 | $202K | 71K |
| 2025-06-09 | Freund John Gordon | Director | Exercise or conversion | 15K | $13.45 | $202K | 77K |
| 2025-05-15 | Paya Carlos V | Director | Grant | 20K | $0.00 | $0 | 20K |
| 2025-05-15 | SANTINI GINO | Director | Grant | 10K | $0.00 | $0 | 85K |
| 2025-05-15 | Freund John Gordon | Director | Grant | 10K | $0.00 | $0 | 62K |
| 2025-05-15 | Balice-Gordon Rita J. | Director | Grant | 10K | $0.00 | $0 | 56K |
| 2025-05-15 | BOHLIN GAREN G | Director | Grant | 10K | $0.00 | $0 | 62K |
| 2025-05-15 | Lurker Nancy | Director | Grant | 10K | $0.00 | $0 | 23K |
| 2025-05-15 | Fallon John A. | Director | Grant | 10K | $0.00 | $0 | 65K |
| 2025-03-21 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 19K | $30.03 | $567K | 104K |
| 2025-03-21 | Tupper Colleen | EVP & Chief Financial Officer | Sell | 6K | $30.03 | $192K | 157K |
| 2025-03-20 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 2K | $30.00 | $58K | 122K |
| 2025-03-20 | Tupper Colleen | EVP & Chief Financial Officer | Sell | 1K | $30.00 | $36K | 163K |
| 2025-03-17 | Dieter David | EVP & General Counsel | Grant | 68K | $0.00 | $0 | 68K |
| 2025-03-14 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 2K | $30.00 | $68K | 124K |
| 2025-03-14 | Tupper Colleen | EVP & Chief Financial Officer | Sell | 977 | $30.00 | $29K | 164K |
| 2025-03-11 | Tupper Colleen | EVP & Chief Financial Officer | Sell | 10K | $30.01 | $313K | 165K |
| 2025-03-11 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 15K | $30.00 | $462K | 127K |
| 2025-03-07 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 2K | $30.00 | $70K | 142K |
| 2025-03-07 | Tupper Colleen | EVP & Chief Financial Officer | Sell | 2K | $30.00 | $45K | 176K |
| 2025-03-06 | Kuhlmann Shirley R. | EVP and General Counsel | Sell | 26K | $28.50 | $743K | 108K |
| 2025-03-06 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 3K | $30.00 | $99K | 144K |
| 2025-03-06 | Tupper Colleen | EVP & Chief Financial Officer | Sell | 2K | $30.00 | $58K | 177K |
| 2025-03-06 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 15K | $30.00 | $462K | 127K |
| 2025-03-05 | Kuhlmann Shirley R. | EVP and General Counsel | Sell | 20K | $28.03 | $561K | 134K |
| 2025-03-04 | Kuhlmann Shirley R. | EVP and General Counsel | Exercise or conversion | 40K | $24.03 | $961K | 194K |
| 2025-03-04 | Kuhlmann Shirley R. | EVP and General Counsel | Sell | 40K | $28.08 | $1.1M | 154K |
| 2025-02-10 | Kuhlmann Shirley R. | EVP and General Counsel | Grant | 41K | $0.00 | $0 | 160K |
| 2025-02-10 | Kuhlmann Shirley R. | EVP and General Counsel | Grant | 29K | $0.00 | $0 | 189K |
| 2025-02-10 | Kuhlmann Shirley R. | EVP and General Counsel | Tax withholding | 25K | $30.52 | $768K | 154K |
| 2025-02-10 | Kuhlmann Shirley R. | EVP and General Counsel | Tax withholding | 10K | $30.52 | $300K | 179K |
| 2025-02-10 | Tupper Colleen | EVP & Chief Financial Officer | Tax withholding | 8K | $30.52 | $247K | 201K |
| 2025-02-10 | Tupper Colleen | EVP & Chief Financial Officer | Tax withholding | 22K | $30.52 | $681K | 179K |
| 2025-02-10 | Tupper Colleen | EVP & Chief Financial Officer | Grant | 52K | $0.00 | $0 | 183K |
| 2025-02-10 | Tupper Colleen | EVP & Chief Financial Officer | Grant | 27K | $0.00 | $0 | 210K |
| 2025-02-10 | Dreyer Scott | EVP & Chief Commercial Officer | Grant | 26K | $0.00 | $0 | 177K |
| 2025-02-10 | Dreyer Scott | EVP & Chief Commercial Officer | Grant | 45K | $0.00 | $0 | 151K |
| 2025-02-10 | Dreyer Scott | EVP & Chief Commercial Officer | Tax withholding | 8K | $30.52 | $243K | 169K |
| 2025-02-10 | Dreyer Scott | EVP & Chief Commercial Officer | Tax withholding | 22K | $30.52 | $661K | 148K |
| 2025-02-10 | Smith Thomas B | EVP and Chief Medical Officer | Grant | 34K | $0.00 | $0 | 88K |
| 2025-02-10 | Smith Thomas B | EVP and Chief Medical Officer | Grant | 5K | $0.00 | $0 | 94K |
| 2025-02-10 | Smith Thomas B | EVP and Chief Medical Officer | Tax withholding | 1K | $30.52 | $46K | 92K |
| 2025-02-10 | Smith Thomas B | EVP and Chief Medical Officer | Tax withholding | 4K | $30.52 | $134K | 88K |
| 2025-02-10 | Heffernan Michael Thomas | Director | Grant | 5K | $0.00 | $0 | 50K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON14 Form 144 notices on file for COLL worth $8.6M at the prices reported; 1 in the last 90 days worth $603K. Latest: Dreyer Scott filed on 2026-09-30 to sell 27,419 shares ($603K) from 2026-09-30.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-30 | Dreyer ScottFormer Officer | 27K | $603K | 0.084% | 2026-09-30 | Fidelity Brokerage Services LLC |
| 2026-07-17 | Fallon John A.Former Director | 14K | $497K | 0.043% | 2026-07-17 | Fidelity Brokerage Services LLC |
| 2026-07-15 | Fallon John A.Former Director | 8K | $294K | 0.025% | 2026-07-15 | Fidelity Brokerage Services LLC |
| 2026-05-18 | Freund John GordonDirector | 30 | $1K | 0.000% | 2026-05-18 | Fidelity Brokerage Services LLC |
| 2026-05-15 | Freund John GordonDirector | 4K | $143K | 0.013% | 2026-05-15 | Fidelity Brokerage Services LLC |
| 2026-05-13 | Lurker NancyDirector | 5K | $162K | 0.014% | 2026-05-13 | Fidelity Brokerage Services LLC |
| 2026-05-11 | BOHLIN GAREN GDirector | 9K | $323K | 0.027% | 2026-05-11 | Fidelity Brokerage Services LLC |
| 2026-03-18 | Dieter DavidOfficer | 14K | $488K | 0.044% | 2026-03-18 | Fidelity Brokerage Services LLC |
| 2026-03-09 | Dieter DavidOfficer | 6K | $228K | 0.020% | 2026-03-09 | Fidelity Brokerage Services LLC |
| 2026-03-03 | Dreyer ScottOfficer | 50K | $2.0M | 0.157% | 2026-03-03 | Fidelity Brokerage Services LLC |
| 2025-12-17 | RITA BALICE-GORDONDIRECTOR | 4K | $172K | 0.012% | 2025-12-05 | CHARLES SCHWAB CORP. |
| 2025-12-08 | Dreyer ScottOfficer | 18K | $848K | 0.056% | 2025-12-08 | Fidelity Brokerage Services LLC |
| 2025-11-12 | Fallon John A.Director | 35K | $1.6M | 0.110% | 2025-11-12 | Fidelity Brokerage Services LLC |
| 2025-11-06 | Tupper ColleenOfficer | 30K | $1.2M | 0.095% | 2025-11-06 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON7 holders report 5% or more of COLL in their latest filing, all on Schedule 13G (passive). The largest reported stake is Israel A. Englander at 7.4% of the class (2,400,985 shares), filed 2026-10-08 for an event on 2026-09-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-30 | 13G/Ano. 1 | Vanguard Capital Managementinvestment adviser | 1.6M | 5.0% | 2026-09-30 |
| 2026-10-29 | 13G/Ano. 1 | PRINCIPAL GLOBAL INVESTORSinvestment adviser | 1.5M | 4.7% | 2026-09-30 |
| 2026-10-08 | 13G/Ano. 1 | Israel A. Englanderindividual | 2.4M | 7.4% | 2026-09-30 |
| 2026-10-08 | 13G/Ano. 1 | Millennium Group Management LLCother entity | 2.4M | 7.4% | 2026-09-30 |
| 2026-10-08 | 13G/Ano. 1 | Millennium Management LLCother entity | 2.4M | 7.4% | 2026-09-30 |
| 2026-10-08 | 13G/Ano. 1 | Integrated Core Strategies (US) LLCother entity | 1.9M | 5.8% | 2026-09-30 |
| 2026-08-14 | 13G | Fuller & Thaler Asset Management, Inc.investment adviser | 1.6M | 5.0% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 8 | Finny Kuruvilla, M.D. Ph. D.parent holding company, individual | 1.4M | 4.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 8 | Eventide Asset Management, LLCinvestment adviser | 1.4M | 4.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 8 | Robin C. Johnparent holding company, individual | 1.4M | 4.5% | 2026-03-31 |
| 2026-05-15 | 13G | JANUS HENDERSON GROUP PLCparent holding company | 1.8M | 5.8% | 2026-03-31 |
| 2026-05-14 | 13G/Ano. 1 | Renaissance Technologies Holdings Corporationparent holding company | 1.5M | 4.5% | 2026-01-08 |
| 2026-05-14 | 13G/Ano. 1 | Renaissance Technologies LLCinvestment adviser | 1.5M | 4.5% | 2026-01-08 |
| 2026-05-08 | 13G | Invesco Ltd.parent holding company, investment adviser | 1.6M | 5.0% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 5 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-13 | 13G/Ano. 2 | Rubric Capital Management LPinvestment adviser, partnership | 1.5M | 4.7% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | David Rosenparent holding company, individual | 1.5M | 4.7% | 2025-12-31 |
13F holders
Tracked managers holding COLL at their latest 13F. JSON7 of the 30 tracked managers held COLL at their latest 13F, $104.3M in total at quarter-end prices. Renaissance Technologies is the largest at $49.5M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 1.4M | $49.5M | 0.07% | -103K |
| Millennium Management | 2026-06-30 | 737K | $26.7M | 0.01% | +376K |
| D. E. Shaw & Co. | 2026-06-30 | 338K | $12.2M | 0.01% | -192K |
| AQR Capital Management | 2026-06-30 | 150K | $5.4M | 0.00% | +15K |
| Point72 Asset Management | 2026-06-30 | 114K | $4.1M | 0.00% | new |
| Two Sigma Investments | 2026-06-30 | 107K | $3.9M | 0.00% | -483K |
| Citadel Advisors | 2026-06-30 | 69K | $2.5M | 0.00% | -53K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Collegium Pharmaceutical reported revenue of $199.9M, up 6.3% from the same quarter a year earlier, and net loss of $15.1M (-0.46 diluted EPS). In FY 2025 it generated $329.3M of operating cash flow and spent $25.1M on buybacks.
- Cash
- $129.5M
- Equity
- $311.9M
- Total assets
- $2.14B
- Shares outstanding
- 32,555,613
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $199.9M | -$15.1M | -7.5% | -0.46 |
| Q1 FY 2026 | 2026-03-31 | $193.5M | $14.5M | 7.5% | 0.40 |
| Q4 FY 2025 | 2025-12-31 | $205.4M | $17.0M | 8.3% | 0.46 |
| Q3 FY 2025 | 2025-09-30 | $209.4M | $31.5M | 15.0% | 0.84 |
| Q2 FY 2025 | 2025-06-30 | $188.0M | $12.0M | 6.4% | 0.34 |
| Q1 FY 2025 | 2025-03-31 | $177.8M | $2.4M | 1.4% | 0.07 |
| Q4 FY 2024 | 2024-12-31 | $181.9M | $12.5M | 6.9% | 0.36 |
| Q3 FY 2024 | 2024-09-30 | $159.3M | $9.3M | 5.9% | 0.27 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $780.6M | $62.9M | $329.3M | $1.7M | $25.1M | n/a |
| FY 2024 | 2024-12-31 | $631.4M | $69.2M | $205.0M | $1.7M | $60.0M | n/a |
| FY 2023 | 2023-12-31 | $566.8M | $48.2M | $274.7M | $461K | $75.0M | n/a |
| FY 2022 | 2022-12-31 | $463.9M | -$25.0M | $124.2M | $1.6M | $14.1M | n/a |
| FY 2021 | 2021-12-31 | $276.9M | $71.5M | $103.6M | $1.9M | $47.9M | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Collegium Pharmaceutical in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Collegium Pharmaceutical (COLL), SEC CIK 1267565, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-09.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-30.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-30.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-06-08.JSON and CSV
- Company record
- EDGAR filing index for CIK 1267565Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of COLL is sold short?
5,375,283 shares were held short at the 2026-10-15 settlement, 7.2 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is COLL's daily short volume?
On 2026-11-02, 115,061 of the 185,308 COLL shares reported to FINRA were sold short, 62.1% of the day's reported volume. Short volume is a flow for one day, not a position.
Does COLL have fails to deliver?
The SEC's latest file shows 18 COLL shares failed to deliver at settlement 2026-10-09. Fails are reported per settlement date and published twice a month with a lag.
Are COLL insiders buying or selling?
No open-market insider trades were reported for COLL in the last 90 days. The most recent filings are listed below. Latest filing: SANTINI GINO (Director) on 2026-06-08.
Have COLL insiders filed to sell?
14 Form 144 notices on file for COLL worth $8.6M at the prices reported; 1 in the last 90 days worth $603K. Latest: Dreyer Scott filed on 2026-09-30 to sell 27,419 shares ($603K) from 2026-09-30.
Who owns 5% or more of COLL?
7 holders report 5% or more of COLL in their latest filing, all on Schedule 13G (passive). The largest reported stake is Israel A. Englander at 7.4% of the class (2,400,985 shares), filed 2026-10-08 for an event on 2026-09-30.
What did COLL report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Collegium Pharmaceutical reported revenue of $199.9M, up 6.3% from the same quarter a year earlier, and net loss of $15.1M (-0.46 diluted EPS). In FY 2025 it generated $329.3M of operating cash flow and spent $25.1M on buybacks.
Which tracked 13F managers own COLL?
7 of the 30 tracked 13F managers held COLL shares at their latest filing, $104.3M in all. The largest: Renaissance Technologies (1.4M shares, $49.5M), Izzy Englander's Millennium Management (737K shares, $26.7M), D. E. Shaw & Co. (338K shares, $12.2M), Cliff Asness's AQR Capital Management (150K shares, $5.4M), Steve Cohen's Point72 Asset Management (114K shares, $4.1M), Two Sigma Investments (107K shares, $3.9M). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.